Highlights of Ophthalmology

Register      Login

VOLUME 43 , ISSUE 4ENG ( February, 2015 ) > List of Articles

REVIEW ARTICLE

Present and Possible Therapies for Age-Related Macular Degeneration

Muhammad Khan, Ketan Agarwal, Mohamed Loutfi, Ahmed Kamal

Citation Information : Khan M, Agarwal K, Loutfi M, Kamal A. Present and Possible Therapies for Age-Related Macular Degeneration. 2015; 43 (4ENG):13-17.

DOI: 10.5005/hoo-10101-43404

Published Online: 25-02-2014

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

PDF Share
  1. D. Pascolini and S. P. Mariotti, “Global estimates of visual impairment: 2010,” British Journal of Ophthalmology, vol. 96, no. 5, pp. 614-618, 2012. View at Publisher View at Google Scholar View at Scopus
  2. N. Congdon, B. O'Colmain, C. C. Klaver, et al., “Causes and prevalence of visual impairment among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477-485, 2004. View at Google Scholar
  3. F. L. Ferris III, C. P. Wilkinson, A. Bird, et al., “Clinical classification of age-related macular degeneration,” Ophthalmology, vol. 120, no. 4, pp. 844-851, 2013. View at Google Scholar
  4. L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, “Age-related macular degeneration,” The Lancet, vol. 379, no. 9827, pp. 1728-1738, 2012. View at Google Scholar View at Scopus
  5. U. Chakravarthy, J. Evans, and P. J. Rosenfeld, “Age related macular degeneration,” British Medical Journal, vol. 340, p. c981, 2010. View at Publisher View at Google Scholar View at Scopus
  6. C. G. Owen, Z. Jarrar, R. Wormald, D. G. Cook, A. E. Fletcher, and A. R. Rudnicka, “The estimated prevalence and incidence of late stage age related macular degeneration in the UK,” British Journal of Ophthalmology, vol. 96, no. 5, pp. 752-756, 2012. View at Publisher View at Google Scholar View at Scopus
  7. D. B. Rein, P. Zhang, K. E. Wirth et al., “The economic burden of major adult visual disorders in the United States,” Archives of Ophthalmology, vol. 124, no. 12, pp. 1754-1760, 2006. View at Publisher View at Google Scholar View at Scopus
  8. B. A. Syed, J. B. Evans, and L. Bielory, “Wet AMD market,” Nature Reviews Drug Discovery, vol. 11, no. 11, p. 827, 2012. View at Google Scholar
  9. S. L. Fine, J. W. Berger, M. G. Maguire, and A. C. Ho, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 342, no. 7, pp. 483-492, 2000. View at Publisher View at Google Scholar View at Scopus
  10. H. R. Coleman, C. C. Chan, F. L. Ferris III, and E. Y. Chew, “Age-related macular degeneration,” The Lancet, vol. 372, no. 9652, pp. 1835-1845, 2008. View at Google Scholar
  11. T. H. Tezel, N. S. Bora, and H. J. Kaplan, “Pathogenesis of age-related macular degeneration,” Trends in Molecular Medicine, vol. 10, no. 9, pp. 417-420, 2004. View at Publisher View at Google Scholar View at Scopus
  12. J. Z. Nowak, “Age-related macular degeneration (AMD): pathogenesis and therapy,” Pharmacological Reports, vol. 58, no. 3, pp. 353-363, 2006. View at Google Scholar View at Scopus
  13. Ophthalmologists TRCo, “Statement from The Royal College of Ophthalmologists in response to the positive draft final guidance from NICE for Eylea,” http://www.rcophth.ac.uk/news.asp?itemid=1390&itemTitle=College+Statement+in+response+to+the+positive+draft+final+guidance+from+NICE+for+Eylea%AE+for+th e+treatment+on+wAMD§ion=24§ionTitle=News2013.
  14. Ophthalmologists TRCo, “Bevacizumab (Avastin) use in medical ophthalmology,” http://www.rcophth.ac.uk/core/core_picker/download.asp?id=11812011.
  15. T. Moutray and U. Chakravarthy, “Age-related macular degeneration: current treatment and future options,” Therapeutic Advances in Chronic Disease, vol. 2, no. 5, pp. 325-331, 2011. View at Publisher View at Google Scholar View at Scopus
  16. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432-1444, 2006. View at Publisher View at Google Scholar View at Scopus
  17. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419-1431, 2006. View at Publisher View at Google Scholar View at Scopus
  18. N. M. Bressler, D. S. Boyer, D. F. Williams, et al., “Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials,” Retina, vol. 32, no. 9, pp. 1821-1828, 2012. View at Google Scholar
  19. D. F. Martin, M. G. Maguire, S. L. Fine, et al., “Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results,” Ophthalmology, vol. 119, no. 7, pp. 1388-1398, 2012. View at Google Scholar
  20. U. Chakravarthy, S. P. Harding, C. A. Rogers, et al., “Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial,” The Lancet, vol. 382, no. 9900, pp. 1258-1267, 2013. View at Google Scholar
  21. J. S. Heier, D. Boyer, Q. D. Nguyen et al., “The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing,” Ophthalmology, vol. 118, no. 6, pp. 1098-1106, 2011. View at Publisher View at Google Scholar View at Scopus
  22. J. S. Heier, D. M. Brown, V. Chong, et al., “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration,” Ophthalmology, vol. 119, no. 12, pp. 2537-2548, 2012. View at Google Scholar
  23. Excellence NIfHaC, “Aflibercept solution for injection for treating wet age-related macular degeneration,” 2013.
  24. S. Schaal, H. J. Kaplan, and T. H. Tezel, “Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?” Ophthalmology, vol. 115, no. 12, pp. 2199-2205, 2008. View at Publisher View at Google Scholar View at Scopus
  25. Y. Barak, W. J. Heroman, and T. H. Tezel, “The past, present, and future of exudative age-related macular degeneration treatment,” Middle East African Journal of Ophthalmology, vol. 19, no. 1, pp. 43-51, 2012. View at Publisher View at Google Scholar View at Scopus
  26. A. J. Augustin, S. Puls, and I. Offermann, “Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone,” Retina, vol. 27, no. 2, pp. 133-140, 2007. View at Publisher View at Google Scholar View at Scopus
  27. K. Zhang, L. Zhang, and R. N. Weinreb, “Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma,” Nature Reviews Drug Discovery, vol. 11, no. 7, pp. 541-559, 2012. View at Google Scholar
  28. K. Takahashi, Y. Saishin, Y. Saishin, A. G. King, R. Levin, and P. A. Campochiaro, “Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib,” Archives of Ophthalmology, vol. 127, no. 4, pp. 494-499, 2009. View at Publisher View at Google Scholar View at Scopus
  29. P. A. Campochiaro, “Gene transfer for neovascular age-related macular degeneration,” Human Gene Therapy, vol. 22, no. 5, pp. 523-529, 2011. View at Google Scholar
  30. R. Petrarca, P. U. Dugel, M. Bennett, et al., “Macular epiretinal brachytherapy in treated age-related macular degeneration (meritage): month 24 safety and efficacy results,” Retina, 2013. View at Publisher View at Google Scholar
  31. P. U. Dugel, R. Petrarca, M. Bennett et al., “Macular epiretinal brachytherapy in treated age-related macular degeneration. MERITAGE study: twelve-month safety and efficacy results,” Ophthalmology, vol. 119, no. 7, pp. 1425-1431, 2012. View at Publisher View at Google Scholar View at Scopus
  32. P. U. Dugel, J. D. Bebchuk, J. Nau, et al., “Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET),” Ophthalmology, vol. 120, no. 2, pp. 317-327, 2013. View at Google Scholar
  33. T. L. Jackson, U. Chakravarthy, P. K. Kaiser, et al., “Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study,” Ophthalmology, vol. 120, no. 9, pp. 1893-1900, 2013. View at Google Scholar
  34. J. C. Lai, D. J. Lapolice, S. S. Stinnett et al., “Visual outcomes following macular translocation with 360° peripheral retinectomy,” Archives of Ophthalmology, vol. 120, no. 10, pp. 1317-1324, 2002. View at Google Scholar View at Scopus
  35. C. I. Falkner-Radler, I. Krebs, C. Glittenberg et al., “Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study,” British Journal of Ophthalmology, vol. 95, no. 3, pp. 370-375, 2011. View at Publisher View at Google Scholar View at Scopus
  36. T. H. Tezel and L. V. del Priore, “Repopulation of different layers of host human Bruch's membrane by retinal pigment epithelial cell grafts,” Investigative Ophthalmology and Visual Science, vol. 40, no. 3, pp. 767-774, 1999. View at Google Scholar View at Scopus
  37. S. D. Schwartz, J.-P. Hubschman, G. Heilwell et al., “Embryonic stem cell trials for macular degeneration: a preliminary report,” The Lancet, vol. 379, no. 9817, pp. 713-720, 2012. View at Publisher View at Google Scholar View at Scopus
  38. Z. Yehoshua, P. J. Rosenfeld, and T. A. Albini, “Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures,” Seminars in Ophthalmology, vol. 26, no. 3, pp. 167-180, 2011. View at Publisher View at Google Scholar View at Scopus
  39. S.-Y. Cohen, H. Bourgeois, C. Corbe et al., “Randomized clinical trial france DMLA2: effect of trimetazidine on exudative and nonexudative age-related macular degeneration,” Retina, vol. 32, no. 4, pp. 834-843, 2012. View at Publisher View at Google Scholar View at Scopus.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.